Invivyd (IVVD): 10 Best NASDAQ Stocks Under $5 to Buy Right Now

Invivyd Inc. (NASDAQ:IVVD) is one of the best NASDAQ stocks under $5 to buy right now. On May 14, Invivyd reported earnings for Q1 2026, highlighted by $13.7 million in PEMGARDA net product revenue, which marks a 22% growth compared to Q1 2025. The company ended the quarter with $184.2 million in cash and cash equivalents, supplemented by ~$20 million in gross proceeds from an April at-the-market offering. R&D expenses rose to $30.7 million, and selling, general, & administrative expenses increased to $25.1 million, resulting in a net loss of $41.4 million for the quarter.

The increase in operating expenses was primarily driven by the ongoing DECLARATION Phase 3 clinical trial for VYD2311, an investigational COVID-19 monoclonal antibody candidate. Initial full enrollment for the trial was achieved in March, and a subsequent sample size re-estimation in April added ~500 subjects, shifting the anticipation of top-line data to Q3. Based on an ad hoc safety review, the trial’s Independent Data Monitoring Committee recommended reducing post-dose monitoring from two hours to thirty minutes, eliminated certain follow-up visits, and updated eligibility to include pregnant and breastfeeding women.

Invivyd (IVVD): 10 Best NASDAQ Stocks Under $5 to Buy Right Now

In laboratory assessments, both PEMGARDA and VYD2311 showed continued in vitro neutralizing activity against the SARS-CoV-2 BA.3.2.2 (“Cicada”) variant. Looking forward, Invivyd Inc. (NASDAQ:IVVD) is preparing for the LIBERTY Phase 3 trial comparing VYD2311 to mRNA vaccines, a Phase 2 trial for Long COVID and vaccine injury, and pediatric evaluations via the DRUMMER trial. Beyond COVID-19, the company is advancing its pipeline with development plans for VMS063 for measles and VBY329 for pediatric respiratory syncytial virus/RSV prophylaxis, targeting investigational new drug readiness for both candidates in late 2026.

Invivyd Inc. (NASDAQ:IVVD) develops next‑generation antibody drugs aimed at long‑lasting effectiveness against evolving viruses, utilizing a proprietary platform to deliver durable therapies.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.